| Assessment Status | Rapid Review complete |
| HTA ID | - |
| Drug | Brivaracetam |
| Brand | Briviact® |
| Indication | As adjunctive therapy in the treatment of partial-onset seizures (POS) with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy. |
| Assessment Process | |
| Rapid review commissioned | 15/02/2016 |
| Rapid review completed | 22/03/2016 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended at the submitted price. |
The HSE has approved reimbursement following confidential price negotiations.